A new long-term study has revealed a troubling health trend in the United States: the number of Americans living with both type 2 diabetes and high blood pressure has doubled over the last two decades, with 1 in 8 adults now affected. Even more concerning is the steep rise in mortality risk associated with this dual diagnosis—suggesting that the combo of these two chronic diseases may be deadlier than previously understood.

Published in the peer-reviewed journal Diabetes Care, the study spans nearly 20 years and highlights how a rapidly increasing population is living with multiple metabolic risk factors—a condition that significantly raises the odds of heart disease, stroke, kidney failure, and early death.

Also Read: Cancer Survivors Share The Small Wins That Helped Them Heal

Researchers at Columbia University's Mailman School of Public Health mined health information from close to 49,000 American adults who took part in the National Health and Nutrition Examination Survey from 1999 through 2018. The National Center for Health Statistics conducted the survey, which captures interviews, laboratory tests, and physical exams to measure the health of the country.

According to the study, only 6% of Americans in 1999 suffered from both type 2 diabetes and high blood pressure. By 2018, it had risen to 12%, or about 1 in 8 adults. Those with both conditions were more than twice as likely to die from any cause and three times more likely to die from heart disease than those with neither condition.

"Even having co-existing prediabetes and high blood pressure was linked to up to 19% greater risk of death," said lead researcher Dr. Nour Makarem, assistant professor of epidemiology at Columbia University.

This is important because it indicates that heightened risk begins even before someone officially qualifies by clinical criteria as having diabetes or hypertension.

Also Read: Colon Cancer Is Rising In Millennials- But This One Symptom Still Feels Too Embarrassing To Talk About

Why Type 2 Diabetes And High Blood Pressure Compound Health Risks?

Having either condition on its own—type 2 diabetes or high blood pressure—already raises one's risk for severe complications but when they occur together, their interaction in the cardiovascular system is much more destructive.

Approximately two out of three patients with type 2 diabetes have high blood pressure or are prescribed medication for it. Among individuals with both disease states, about 33% died over a median 9-year follow-up period.

For individuals with only one condition, the mortality rate remained at 20–22%, whereas individuals with neither condition suffered from a mere 6% fatality during the same period of time.

The research identified that in comparison with individuals with:

Hypertension alone, developing both conditions increased the risk for all-cause mortality by 66% as well as cardiovascular death by 54%.

Type 2 diabetes alone, but with both conditions, overall risk of death was 25% higher and greater than two-fold increased cardiovascular mortality.

Why Type 2 Diabetes and High Blood Pressure Pair so Deadly?

Both type 2 diabetes and high blood pressure are "silent killers." Alone, they tend to produce no discernible symptoms until complications—such as stroke, heart failure, or kidney damage—arise. Combined, however, they provide a deadly combination of cardiovascular stress.

Diabetes disables the body's ability to keep blood sugar in balance. High glucose levels destroy blood vessels and organs by repeated damage.

Hypertension makes the heart work harder to circulate blood, which hardens and weakens the arteries.

When both conditions occur together, this speeds up the deterioration of the arteries, kidneys, and heart, making heart attack, stroke, and end-stage renal disease requiring dialysis or transplantation more likely.

Early Warning Signs That Are Often Missed

Another significant takeaway of the research is that the danger of death starts even prior to a full-blown diagnosis. Prediabetic and high-blood-pressure persons—even if they are below diagnostic levels—had a 19% greater risk of mortality.

Although type 2 diabetes can quietly develop without apparent symptoms, there are some early warning signs that should never be overlooked—particularly if you're at risk. The sooner you detect diabetes, the less complicated it is to control and prevent long-term complications. Even slight symptoms deserve a chat with your doctor.

• One of the first and most indicative symptoms of high blood sugar is urinating more often, particularly at night. As blood glucose increases, the kidneys work around the clock to flush out the excess glucose. When they're unable to keep pace, glucose leaks into the urine, causing more frequent trips to the bathroom.

• Too much sugar in the urine not only impacts hydration—but also is a breeding ground for bacteria and yeast. This increases the likelihood of infections in the urinary tract and yeast infections, particularly in women. If you find that you have persistent infections that are difficult to clear, you might want to be tested.

• Another visible clue is the appearance of dark, velvety patches of skin, typically found in body folds like the neck, armpits, or groin. These areas may indicate insulin resistance—a common precursor to diabetes.

• If you’re eating regularly but still feel hungry all the time, your cells may not be properly absorbing glucose. As a result, your body stays in a constant state of seeking energy, driving persistent hunger.

• Ironically, even though you are hungrier, you may actually lose weight unexpectedly. Since there's not enough glucose flowing into cells, your body starts to break down muscle and fat for energy.

• This energy shortage also leads to constant fatigue and weakness. You could be tired, even with a good night's rest. Dehydration caused by frequent urination only adds to that pervasive fatigue.

• Another troubling symptom is blurred vision, which can appear and disappear. High blood glucose can harm the tiny blood vessels in the eyes, leading to more severe conditions—blindness, if not treated.

• Most people experience a tingling or numb feeling in their hands or feet. This is caused by nerve damage from years of high blood sugar levels. Refereed to as diabetic neuropathy, this can also result in long-term chronic pain or loss of sensation.

This result highlights the importance of early screening and proactive prevention measures, particularly for individuals in their 30s and 40s who are unaware they're at risk. The research also reignites debate around various forms of diabetes, many of which have different risks:

Type 1 Diabetes: Autoimmune condition in which the pancreas releases no insulin.

Type 2 Diabetes: A metabolic disorder in which the body fails to utilize insulin. Frequently associated with obesity, a diet lacking in nutritious foods, and physical inactivity.

Prediabetes: A silent diabetes precursor with no warning signs.

Gestational Diabetes: Appears during pregnancy and increases risk of type 2 diabetes in the future.

Of these, type 2 diabetes is the most common and can be directly associated with lifestyle modifications that are often possible.

This highlights the pressing need for public health approaches to prevent and manage these diseases and to halt these negative trends," Dr. Makarem stressed.

At present, approximately two-thirds of adults with diabetes have blood pressure above 130/80 mm Hg or are taking antihypertensive therapy.

Since most symptoms are mild or undetectable, screening is necessary on a regular basis. The American Diabetes Association suggests that all adults over the age of 45 should be screened for diabetes. If you are younger but have risk factors that include obesity, being inactive, having a poor diet, or a family history of diabetes, you need to be tested too.

Screening is typically a straightforward blood test. If normal, the ADA recommends repeat testing at three-year intervals to track changes.

As an ageing population, inactive lifestyles and obesity on the rise, the co-epidemic of diabetes and high blood pressure is set to expand unless there are systemic changes.

In a growing food safety alert, the U.S. Food and Drug Administration (FDA) has escalated a butter recall to a Class II risk level following concerns over undeclared allergens. The product in question, European Style Butter Blend manufactured by Bunge North America Inc., was found to contain milk that was not listed on the packaging label.

Class II Recall Indicates Moderate Health Risk

The risk reclassification, issued on Wednesday, July 30, places the product under the FDA’s second-highest warning level. According to the FDA, a Class II recall involves “a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.”

While no illnesses or allergic reactions have been reported so far, the undeclared presence of milk poses a potential health hazard to people with dairy allergies or lactose intolerance.

Initial Voluntary Recall Announced in Mid-July

The recall began as a voluntary measure by Bunge on July 14, when the company announced it was pulling approximately 64,800 pounds, or 1,800 cases, of its one-pound butter blocks from shelves. The recalled butter was packed in white paperboard cases, each containing 36 one-pound blocks.

The affected products carry the lot code 5064036503 and were shipped to 12 distribution centers across the United States and one in the Dominican Republic.

Why the Undeclared Milk Is a Serious Concern

Milk is one of the nine major food allergens identified by the FDA, alongside eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, soybeans, and sesame. The FDA mandates clear labeling of such allergens because exposure, even in small amounts, can cause a range of reactions, from mild discomfort to life-threatening symptoms.

Food-related allergic reactions may include hives, facial swelling, vomiting, coughing, and skin irritation. More severe responses can result in anaphylaxis, a rapid-onset, whole-body allergic reaction that may lead to shock and, in extreme cases, death.

According to the Mayo Clinic, anaphylaxis occurs when the immune system floods the body with chemicals in response to an allergen. This can cause a sudden drop in blood pressure, narrowing of the airways, and potential organ failure if not treated immediately.

FDA Reiterates Importance of Allergen Labeling

In light of the recall, the FDA has emphasized the importance of allergen labeling and said it continues to enforce regulations requiring companies to clearly list all ingredients and potential allergens on packaging.

“More specific labeling requirements exist for foods that can cause allergies or other hypersensitivity reactions,” the agency stated. “These rules are designed to prevent accidental consumption of allergens and to protect consumers with dietary restrictions.”

The FDA also advised that anyone who experiences symptoms of an allergic reaction after consuming the recalled butter should “stop eating the food immediately, evaluate the need to use emergency medication (such as epinephrine), and seek medical attention.”

Company Yet to Comment

As of August 2, Bunge North America has not issued an updated public statement in response to the FDA’s reclassification and did not respond to a request for comment.

Food Safety Under Scrutiny Amid Other Recent Recalls

This butter recall follows a string of other high-profile food safety incidents this year. In recent weeks, more than 110,000 cases of popular chocolate ice cream bars were recalled across 23 states. Target-branded baby food was also pulled from shelves for containing “elevated levels of lead.”

Not forever, but what if you could press pause on Alzheimer’s just long enough to enjoy a few more good years? That is the tantalising promise behind a new drug called lecanemab, hailed as a game-changer in the fight against dementia.

The drug has already been licensed for use in the UK after trials showed it could slow the pace of decline in people with early-stage Alzheimer’s. But new long-term findings are turning cautious hope into something stronger: patients who stayed on lecanemab for four years experienced a noticeable delay in the disease's progression. Some even showed no decline at all.

How It Works

In the initial 18-month trial, the drug delayed Alzheimer’s progression by just under six months. That might not sound like much, but it’s the long game that matters here. Among 478 patients who remained on the drug for four years, the average delay before their disease advanced to the next stage stretched to almost 11 months.

Even more striking: 69 per cent of those with low levels of tau saw no decline at all over the four years. And over half in that same group actually improved their cognitive scores.

A Slow Slide Instead of a Steep Drop

Typically, people with mild Alzheimer’s see their scores on memory and function tests worsen by one or two points each year. But for those taking lecanemab, the total decline across four years was just 1.75 points. That’s a major shift in the rhythm of the disease, changing it from a downhill tumble to a slow shuffle.

Professor Christopher Van Dyck, who led the study at Yale School of Medicine, puts it simply: “You will get worse over time, but it will take longer to get there.” That extra time could mean more independence, more connection with loved ones, and more living.

Why Early Treatment is Key

This makes a strong case for early diagnosis and intervention, which could shift the way we approach Alzheimer’s care. No longer is it just about managing symptoms; it’s about changing the trajectory of the disease.

Not a Cure, But a Clear Step Forward

Lecanemab isn’t a miracle cure. It doesn’t reverse Alzheimer’s, and it’s not suitable for all patients. But experts say it’s a major milestone. Reportedly, this is the first wave of disease-modifying treatments and there’s still plenty to understand.

Other Contenders in the Ring

Lecanemab isn’t the only drug showing promise. A similar treatment called donanemab was tested over a three-year period, though it was only administered for 18 months. Still, the results were encouraging: patients on the drug gained an extra six to 12 months before their disease progressed.

That might not sound earth-shattering, but in a condition where time is everything, even a few more months of clarity and connection can be priceless.

The research is still evolving, but the signs are encouraging. With continued trials, this could be the start of a new chapter in dementia treatment, one where patients and families have more time to prepare, more time to enjoy life, and more hope than ever before.

When 63-year-old John Starns slumped on a train station bench in Sevenoaks, drenched in sweat and struggling to stay upright, most passers-by assumed he was drunk. He looked wobbly, pale, and visibly disoriented. But what looked like an awkward case of public intoxication turned out to be something far more sinister: a brain tumour hiding behind symptoms commonly mistaken for vertigo.

From “It’s Just Vertigo” to “You Have a Brain Tumour”

Three months and one MRI scan later, John finally got the truth. He reportedly had a vestibular schwannoma, a rare, benign brain tumour sitting on the nerve that connects the brain to the inner ear. It was affecting his balance, hearing, and overall coordination, symptoms that, in hindsight, were never typical of garden-variety vertigo.

What is Vestibular Schwannoma?

That is why the symptoms can masquerade as something much less serious.

• Dizziness or vertigo
• Hearing loss in one ear
• Ringing or buzzing sounds (tinnitus)
• Poor sound localisation
• In more advanced cases, numbness on one side of the face

Because these tumours grow at a glacial pace, symptoms tend to hide for months or even years. According to Cancer Research UK, they account for around 8 per cent of all brain tumours, with risk increasing significantly after the age of 65. In rare cases, they are linked to a genetic condition called neurofibromatosis, which often causes tumours on both sides of the brain.

Why Dizziness Deserves a Second Look

For John, it was not just one woozy episode. It was a string of unsettling, spin-the-room moments that left him lying flat on his back, eyes squeezed shut, praying for the world to stop pirouetting. And while vertigo was the first suspect, his brain had other plans, like growing a tumour on his vestibulocochlear nerve.

That is the thing with dizziness: it is vague, common, and often misunderstood. It can signal anything from low blood pressure and ear infections to neurological conditions that need serious medical attention. But because it is so easy to dismiss and hard to describe without wildly gesturing, it often gets brushed under the rug until it insists on being noticed.

If you face dizziness, do not ignore it. Especially if the dizziness is intense, recurrent, or comes with sidekicks like hearing loss, balance issues, or ringing in your ears.